NIAID-Led Study of mRNA Vaccine Supports Advance to Phase 3 Human Trials
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and at Moderna, Inc., Cambridge, Massachusetts. The animal study results published online today in the New England Journal of Medicine complement recently reported interim results from an NIAID-sponsored Phase 1 clinical trial of mRNA-1273. The candidate mRNA-1273 vaccine is manufactured by Moderna.
In this study, three groups of eight rhesus macaques received two injections of 10 or 100 micrograms (µg) of mRNA-1273 or a placebo. Injections were spaced 28 days apart. Vaccinated macaques produced high levels of neutralizing antibodies directed at the surface spike protein used by SARS-CoV-2 to attach to and enter cells. Notably, say the investigators, animals receiving the 10-µg or 100-µg dose vaccine candidate produced neutralizing antibodies in the blood at levels well above those found in people who recovered from COVID-19.
The experimental vaccine also induced Th1 T-cell responses but not Th2 responses. Induction of Th2 responses has been associated with a phenomenon called vaccine-associated enhancement of respiratory disease (VAERD). Vaccine-induced Th1 responses have not been associated with VAERD for other respiratory diseases. In addition, the experimental vaccine induced T follicular helper T-cell responses that may have contributed to the robust antibody response.
Four weeks after the second injection, all the macaques were exposed to SARS-CoV-2 via both the nose and the lungs. Remarkably, after two days, no replicating virus was detectable in the lungs of seven out of eight of the macaques in both vaccinated groups, while all eight placebo-injected animals continued to have replicating virus in the lung. Moreover, none of the eight macaques vaccinated with 100 µg of mRNA-1273 had detectable virus in their noses two days after virus exposure. This is the first time an experimental COVID-19 vaccine tested in nonhuman primates has been shown to produce such rapid viral control in the upper airway, the investigators note. A COVID-19 vaccine that reduces viral replication in the lungs would limit disease in the individual, while reducing shedding in the upper airway would potentially lessen transmission of SARS-CoV-2 and consequently reduce the spread of disease, they add.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- CDC study describes safety profile of second mRNA COVID booster
The CDC investigates the safety profile of a fourth dose of mRNA-based COVID-19 vaccines in people aged 50 years and older.
- LA County and Long Beach offer Novavax, the new COVID-19 vaccine
Doctors say Novavax, a new COVID-19 vaccine, is protein-based and doesn’t contain genetic material. Will folks who aren’t vaccinated go for the shot?
- Frederick County Health Department to start offering Novavax vaccine
The Frederick County Health Department on Wednesday will start offering the two-dose, protein-based Novavax COVID-19 vaccine to adults not yet vaccinated against the virus.
- Novavax vaccine now available for Clark County residents
Appointments to get the monkeypox vaccine are available for individuals at higher risk of exposure, the Southern Nevada Health District said Friday in a news release.
- Novavax COVID-19 vaccine now available to adults in Clark County
The protein-based Novavax COVID-19 vaccine is now available to Clark County residents over the age of 18, the Southern Nevada Health District announced on Monday.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- US Government Purchases 66 Million Doses of Moderna’s COVID-19 Booster Candidate
The US government has agreed to purchase 66 million doses of the company’s COVID-19 vaccine booster candidate, mRNA-1273.222, for $1.74 billion. The bivalent candidate contains the Spikevax vaccine, ...
- Moderna to Supply New COVID-19 Vaccine Booster Under $1.74B Contract With US Government
Moderna (Nasdaq: MRNA) has received a potential $1.74 billion contract to initially produce and deliver 66 million doses of its COVID-19 vaccine booster candidate to the U.S. government. The contract ...
- Moderna signs contract to supply Covid-19 booster vaccines to the US
Moderna has entered a supply contract with the US government to deliver 66 million doses of Covid-19 vaccine booster candidate, mRNA-1273.222.
- News - mRNA-1273.222
US mRNA specialist Moderna on Friday announced that the US government has secured 66 million doses of a Moderna COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate ...
- U.S. to buy 66M doses of Moderna's bivalent Omicron-adapted booster shots for $1.74B
The U.S. will buy 66M doses of Moderna's (MRNA) bivalent COVID-19 vaccine for up to $1.74B, in a move to beef up supplies of the upgraded booster shot ahead of the fall & winter season ...